Platinum Priority – Prostate Cancer
Editorial by Martin Gleave and Kim Chi on pp. 61–63 of this issue

Molecular Characterization of Enzalutamide-treated Bone Metastatic Castration-resistant Prostate Cancer

By: Eleni Efstathiou a b , Mark Titus a , Sijin Wen a , Anh Hoang a , Maria Karlou a , Robynne Ashe a , Shi Ming Tu a , Ana Aparicio a , Patricia Troncoso c , James Mohler d and Christopher J. Logothetis a lowast

European Urology, Volume 67 Issue 1, January 2015, Pages 53-60

Published online: 01 January 2015

Keywords: Enzalutamide, Castration-resistant prostate cancer, Predictors of outcome, Bone metastasis, Bone tumor microenvironment, Adaptive feedback mechanism, Androgen receptor, Primary resistance to enzalutamide, Androgen signaling inhibition, Tissue-based research

Abstract Full Text Full Text PDF (1,7 MB) Patient Summary

Patient Summary We report a first bone biopsy study in metastatic prostate cancer in humans that searched for predictors of outcome of enzalutamide therapy. Benefit is linked to a pretreatment androgen-signaling signature.

Place a comment

Your comment *

max length: 5000